| Novartis voices excitement over Ilaris approval | Posted on 18/06/2009 in Pharmaceutical Company Product News Novartis is excited about the first approval of Ilaris (canakinumab), it has said.
Based on its potential to meet an important clinical need, the Food and Drug Administration has permitted the medication to treat adults and children with cryopyrin-associated periodic syndrome (CAPS).
Dr Hal Hoffman, associate professor of pediatrics and medicine at the University of California, explained there have been limited traditional medications available for patients with the condition up until now.
He added it is a life-long disease and it is extremely important for sufferers to have access to convenient therapies as they have to deal with distressing and deliberating symptoms on a daily basis.
"We are excited about this first Ilaris approval, which reflects our commitment to developing innovative treatments that address unmet medical needs, regardless of the size of the patient population," Dr Hoffman stated.
Earlier this month, Novartis announced it had successfully demonstrated the full potential of cell-based technology for the production of an A(H1N1) vaccine.
Based on results from investigations, the company is now able to manufacture and produce the preventative medication.Other news stories from 18/06/2009
Read more in the Zenopa News Archive
How this news is generated
|  |
|
